Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
AstraZeneca
Harvard Business School
Johnson and Johnson
Mallinckrodt

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,058,467

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,058,467 protect, and when does it expire?

Patent 8,058,467 protects VYZULTA and is included in one NDA.

This patent has forty-nine patent family members in thirty-six countries.

Summary for Patent: 8,058,467
Title:Prostaglandin derivatives
Abstract: Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
Inventor(s): Ongini; Ennio (Milan, IT), Chiroli; Valerio (Milan, IT), Benedini; Francesca (Milan, IT), Soldato; Piero Del (Monza, IT)
Assignee: Nicox S.A. (Sophia Antipolis-Valbonne, FR)
Application Number:13/025,740
Patent Claim Types:
see list of patent claims
Use; Compound;

Drugs Protected by US Patent 8,058,467

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bausch And Lomb VYZULTA latanoprostene bunod SOLUTION/DROPS;OPHTHALMIC 207795-001 Nov 2, 2017 RX Yes Yes   Start Trial   Start Trial Y REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,058,467

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
04100001Jan 5, 2004

International Family Members for US Patent 8,058,467

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 047081   Start Trial
Argentina 098931   Start Trial
Australia 2004313688   Start Trial
Brazil PI0418245   Start Trial
Canada 2551409   Start Trial
China 100469765   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
AstraZeneca
Medtronic
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.